Acutus Names David Roman As New CEO; Mickelsen Departs Company
Executive Summary
After announcing that its estimated second-quarter 2022 revenue exceeded analysts’ expectations, Acutus announced that David Roman, the interim CEO and CFO, is now the permanent CEO. Also, Steven Mickelsen announced that he is stepping down as Acutus’ chief translational science officer.
You may also be interested in...
News We’re Watching: Apple/Masimo Patent Fight Update; Acutus Winds Down; Illumina Bails On Grail
Medtech Insight's News We're Watching highlights medtech industry developments that you may have missed over the last few weeks. In addition to the big news from Acutus, Apple, and Illumina, Masimo scored an important FDA clearance, Beta Bionics announced the US launch of its iLet bionic pancreas for Dexcom’s G7 CGM, and more.
Cardio Conversations: Steven Mickelsen Discusses PFA, Electrophysiology And What It Takes To Be A Physician Inventor
In the first episode of Medtech Insight’s new podcast series focused on cardiovascular technology, editor Reed Miller talks to Steven Mickelsen, one of the founders of Farapulse and Field Medical, about pulsed field ablation, an emerging technology that is changing electrophysiology.
Minute Insight: Acutus Adds Another Device To The Left-Heart Business It Sold To Medtronic
The company announced the US launch of the AcQCross Qx transseptal dilator/needle. It is specifically designed to help deploy Boston Scientific’s Watchman left-atrial appendage closure device, but it is part of the left-heart access device portfolio that Acutus recently sold to Medtronic.